Navigation Links
Caliper Life Sciences' Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
Date:4/28/2008

- IVIS Imaging System Provides Real-Time Insight on Viability of Infectious

Disease Treatment Options -

HOPKINTON, Mass., April 28 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced that the Texas A&M Health Science Center Research Foundation (HSCRF) is using the IVIS Spectrum imaging system to speed the development of more effective therapeutic treatments for tuberculosis. Research efforts and the purchase of the IVIS system are funded through a grant to the Texas A&M Health Science Center from the Bill & Melinda Gates Foundation.

Tuberculosis currently affects nearly one-third of the world's population and remains a global threat due to severe and drug-resistant strains. According to the World Health Organization, tuberculosis is one of the most serious infectious diseases in the world. Caliper is dedicated to assisting the global fight against infectious diseases and aiding the discovery of life-saving treatments.

Researchers at the Texas A&M Health Science Center College of Medicine and a consortium of leading tuberculosis researchers at Washington University and Stanford University School of Medicine are actively studying tuberculosis infections in live animals using in vivo imaging technology. Caliper's IVIS Spectrum was specifically chosen for its highly sensitive luminescence detection and ability to successfully image, track and quantify tuberculosis infections using fluorescence. The IVIS system enables researchers to visualize the progression of the disease and impact of therapeutic candidates in real time. This rapid evaluation of in vivo efficacy allows researchers to quickly adapt efforts and progress towards effective treatments for the disease.

"We are quite optimistic that this research collaboration will uncover new and promising discoveries in the fight against tuberculosis," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Caliper's imaging technology has proven to be integral in other discovery efforts for finding new ways and treatments to combat infectious disease. This is a great opportunity to exploit Caliper's imaging technology to make a major impact in this world."

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper and IVIS are registered trademarks, and Spectrum is a trademark, of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/17/2017)... , Jan. 17, 2017 North America Insulin ... new report, "North America Insulin Delivery Market Outlook to ... Insulin Delivery market. The report provides value, in millions ... (USD) within market segments - Insulin Pens, Insulin Pumps, ... report also provides company shares and distribution shares data ...
Breaking Medicine Technology:
(Date:1/18/2017)... ANN ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, ... ... (PRWEB) January 18, 2017 -- Global public ... pitcher to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: ... Standard for drinking water treatment units. This certification verifies that ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family managed ... in central Maryland and the DC region, is inaugurating a charity event aimed at ... every year, making it the #1 killer in America. However, heart disease is largely ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. ... website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President ... the field of biosimilars through thought leader interaction in, live video and interactive ...
(Date:1/17/2017)... ... 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now in its ... corners and commit the crime of stalking, a very real danger to many in our ... factor in stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, ... Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, ... endure and pass through tough times, Dr. Bernie Siegel energizes listeners to live ...
Breaking Medicine News(10 mins):